Pancreatic Insulin Production Capacity (PIPC) - a Feasibility Study

Condition(s) studied

Investigational drug(s) / intervention(s)

Boost Original meal replacement shake: One bottle of Boost Original meal replacement shake.

Study summary

The standard treatment for Type 2 diabetes involves management of the disease based on average of blood glucose control over the past few months.

In this study, the investigators test for the participants' ability to produce insulin, which is the hormone that the body makes to control blood sugar levels. The body produces insulin in response to eating. The participants will drink a meal replacement shake, and then test the blood for levels of insulin produced over 2 hours.

With blood tests taken five times over two hours, the investigators will measure the blood glucose (sugar), and insulin levels. This study will assess the differences in insulin produced in the participants and try to understand the reasons for these differences.

Eligibility

Primary outcome measure(s)

• Pancreatic insulin production capacity (PIPC) represented by the participant's insulin and C-peptide levels after drinking the meal replacement shake. — 12 months
  Participants will get blood drawn at time 0, 30, 60, 90, and 120 minutes. Blood will be sent for glucose, insulin, and C-peptide measurements. The area under the curve (AUC) will be calculated from these measurements. The AUC for insulin and for C-peptide will be representative of the participant's PIPC.

Trial sites (1)

More Ottawa Hospital Research Institute trials in Canada

Other trials for the same condition